Dickkopf-1: a suitable target for the management of myeloma bone disease

Bibliography

• Heider U, Hofbauer LC, Zavrski I, et al. Novel aspects of osteoclast activation and osteoblast inhibition in myeloma bone disease. Biochem Biophys Res Commun 2005;338:687-93
   PubMed Web of Science ®Google Scholar
• Terpos E, Dimopoulos MA. Myeloma bone disease: pathophysiology and management. Ann Oncol 2005;16:1223-31
   PubMed Web of Science ®Google Scholar
• Sezer O, Heider U, Zavrski I, et al. RANK ligand and osteoprotegerin in myeloma bone disease. Blood 2003;101:2094-8
   PubMed Web of Science ®Google Scholar
• Lentzsch S, Ehrlich LA, Roodman GD. Pathophysiology of multiple myeloma bone disease. Hematol Oncol Clin North Am 2007;21:1035-49
   PubMed Web of Science ®Google Scholar
• Giuliani N, Morandi F, Tagliaferri S, et al. Production of Wnt inhibitors by myeloma cells: potential effects on canonical Wnt pathway in the bone microenvironment. Cancer Res 2007;67:7665-74
   PubMed Web of Science ®Google Scholar
• Giuliani N, Rizzoli V, Roodman GD. Multiple myeloma bone disease: pathophysiology of osteoblast inhibition. Blood 2006;108:3992-6
   PubMed Web of Science ®Google Scholar
• Qiang YW, Chen Y, Stephens O, et al. Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma. Blood 2008;112:196-207
   PubMed Web of Science ®Google Scholar
• Pinzone J, Hall BM, Thudi NK, et al. The role of Dickkopf-1 in bone development, homeostasis and disease. Blood 2009;113:517-25
   PubMed Web of Science ®Google Scholar
• Westendorf JJ, Kahler RA, Schroeder TM. Wnt signaling in osteoblasts and bone diseases. Gene 2004;341:19-39
   PubMed Web of Science ®Google Scholar
• Clevers H. Wnt/β-catenin signaling in development and disease. Cell 2006;127:469-80
   PubMed Web of Science ®Google Scholar
• Niida A, Hiroko T, Kasai M, et al. DKK1, a negative regulator of Wnt signaling, is a target of the β-catenin/TCF pathway. Oncogene 2004;23:8520-6
   PubMed Web of Science ®Google Scholar
• Piters E, Boudin E, Van Hul WV. Wnt signaling: a win for bone. Arch Biochem Biophys 2008;473:112-6
   PubMed Web of Science ®Google Scholar
• Liu C, Li Y, Semenov M, et al. Control of β-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell 2002;108:837-47
   PubMed Web of Science ®Google Scholar
• Kawano Y, Kypta R. Secreted antagonists of the Wnt signaling pathway. J Cell Sci 2003;116:2627-34
   PubMed Web of Science ®Google Scholar
• Zeng X, Huang H, Tamai K, et al. Initiation of Wnt signaling: control of Wnt coreceptor Lrp6 phosphorylation/activation via frizzled, dishevelled and axin functions. Development 2008;135:367-75
   PubMed Web of Science ®Google Scholar
• Tolwinski NS, Wehrli M, Rives A. Wg/Wnt signal can be transmitted through Arrow/LRP5,6 and Axin independently of Zw3/Gsk3β activity. Dev Cell 2003;4:407-18
   PubMed Web of Science ®Google Scholar
• Colla S, Zhan F, Xiong W, et al. The oxidative stress response regulates DKK1 expression through the JNK signaling cascade in multiple myeloma plasma cells. Blood 2007;109:4470-7
   PubMedGoogle Scholar
• Logan CY, Nusse R. The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol 2004;20:781-810
   PubMed Web of Science ®Google Scholar
• Gong Y, Slee RB, Fukai N, et al. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 2001;107:513-23
   PubMed Web of Science ®Google Scholar
• Tamai K, Zeng X, Liu C, et al. A mechanism for Wnt coreceptor activation. Mol Cell 2004;13:149-56
   PubMed Web of Science ®Google Scholar
• Tamai K, Semenov M, Kato Y, et al. LDL-receptor-related proteins in Wnt signal transduction. Nature 2000;407:530-5
   PubMed Web of Science ®Google Scholar
• Schweizer L, Varmus H. Wnt/Wingless signaling through β-catenin requires the function of both LRP/Arrow and frizzled classes of receptors. BMC Cell Biol 2003;4:4. Published online 2 May 2003, doi:10.1186/1471-2121-4-4
   PubMed Web of Science ®Google Scholar
• Bafico A, Liu G, Yaniv A, et al. Novel mechanism of Wnt signalling inhibition mediated by Dickkopf-1 interaction with LRP6/Arrow. Nat Cell Biol 2001;3:683-6
   PubMed Web of Science ®Google Scholar
• Mao B, Wu W, Davidson G, et al. Kremen proteins are Dickkopf receptors that regulate Wnt/β-catenin signalling. Nature 2002;417:664-7
   PubMed Web of Science ®Google Scholar
• Mao B, Niehrs C. Kremen2 modulates Dickkopf2 activity during Wnt/LRP6 signaling. Gene 2003;302:179-83
   PubMed Web of Science ®Google Scholar
• Davidson G, Mao B, del Barco Barrantes I, Niehrs C. Kremen proteins interact with Dickkopf-1 to regulate anteroposterior CNS patterning. Development 2002;129:5587-96
   PubMed Web of Science ®Google Scholar
• Mao B, Wu W, Li Y, et al. LDL-receptor-related protein 6 is a receptor for Dickkopf proteins. Nature 2001;411:321-5
   PubMed Web of Science ®Google Scholar
• Huang HC, Klein PS. The Frizzled family: receptors for multiple signal transduction pathways. Genome Biol 2004;5:234. Published online 14 June 2004, doi:10.1186/gb-2004-5-7-234
   PubMed Web of Science ®Google Scholar
• Fujita K, Janz S. Attenuation of WNT signaling by DKK-1 and -2 regulates BMP2-induced osteoblast differentiation and expression of OPG, RANKL and M-CSF. Mol Cancer 2007;6:71. Published online 30 October 2007, doi:10.1186/1476-4598-6-71
   PubMed Web of Science ®Google Scholar
• Khan Z, Vijayakumar S, de la Torre T, et al. Analysis of endogenous LRP6 function reveals a novel feedback mechanism by which Wnt negatively regulates its receptor. Mol Cell Biol 2007;27:7291-301
   PubMedGoogle Scholar
• Nagasawa T, Hirota S, Tachibana K, et al. Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature 1996;382:635-8
   PubMed Web of Science ®Google Scholar
• Døsen G, Tenstad E, Nygren M-K, et al. Wnt expression and canonical Wnt signaling in human bone marrow B lymphopoiesis. BMC Immunol 2006;7:13, 29 June 2006, doi:10.1186/1471-2172-7-13
   PubMed Web of Science ®Google Scholar
• Koch U, Wilson A, Cobas M, et al. Simultaneous loss of β- and γ-catenin does not perturb hematopoiesis or lymphopoiesis. Blood 2008;111:160-4
   PubMed Web of Science ®Google Scholar
• Willert K, Brown JD, Danenberg E, et al. Wnt proteins are lipid-modified and can act as stem cell growth factors. Nature 2003;423:448-52
   PubMed Web of Science ®Google Scholar
• Krupnik VE, Sharp JD, Jiang C, et al. Functional and structural diversity of the human Dickkopf gene family. Gene 1999;238:301-13
   PubMed Web of Science ®Google Scholar
• Fedi P, Bafico A, Nieto Soria A, et al. Isolation and biochemical characterization of the human Dkk-1 homologue, a novel inhibitor of mammalian Wnt signaling. J Biol Chem 1999;274:19465-72
   PubMed Web of Science ®Google Scholar
• Tada M, Smith JC. Xwnt11 is a target of Xenopus Brachyury: regulation of gastrulation movements via Dishevelled, but not through the canonical Wnt pathway. Development 2000;127:2227-38
   PubMed Web of Science ®Google Scholar
• Mukhopadhyay M, Shtrom S, Rodriguez-Esteban C, et al. Dickkopf 1 is required for embryonic head induction and limb morphogenesis in the mouse. Dev Cell 2001;1:423-34
   PubMed Web of Science ®Google Scholar
• Hideshima T, Mitsiades C, Tonon G, et al. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutics targets. Nat Rev Cancer 2007;7:585-98
   PubMed Web of Science ®Google Scholar
• Morvan F, Boulukos K, Clement-Lacroix P, et al. Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass. J Bone Miner Res 2006;21:934-45
   PubMed Web of Science ®Google Scholar
• Pinson KI, Brennan J, Monkley S, et al. An LDL-receptor-related protein mediates Wnt signalling in mice. Nature 2000;407:535-8
   PubMed Web of Science ®Google Scholar
• Lorenzo J, Horowitz M, Choi M. Osteoimmunology: interactions of the bone and the immune system. Endocr Rev 2008;29:403-40
   PubMed Web of Science ®Google Scholar
• Teitelbaum SL. Bone resorption by osteoclasts. Science 2000;289:1504-08
   PubMed Web of Science ®Google Scholar
• Kong YY, Yoshida H, Sarosi I, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999;397:315-23
   PubMed Web of Science ®Google Scholar
• Terpos E, Szydlo R, Apperley JF, et al. Soluble receptor activator of nuclear factor κB ligand–osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood 2003;102:1064-9
   PubMed Web of Science ®Google Scholar
• Silvestris F, Cafforio P, Tucci M, et al. Upregulation of osteoblast apoptosis by malignant plasma cells: a role in myeloma bone disease. Br J Haematol 2003;122:39-52
   PubMed Web of Science ®Google Scholar
• Boyden LM, Mao J, Belsky J, et al. High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med 2002;346:1513-21
   PubMed Web of Science ®Google Scholar
• Little RD, Carulli JP, Del Mastro RG, et al. A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am J Hum Genet 2002;70:11-9
   PubMed Web of Science ®Google Scholar
• MacDonald BT, Joiner DM, Oyserman SV, et al. Bone mass is inversely proportional to DKK1 levels in mice. Bone 2007;41:331-9
   PubMed Web of Science ®Google Scholar
• Staal FJ, Clevers HC. WNT signaling and haematopoiesis: a WNT-WNT situation. Nat Rev Immunol 2005;5:21-30
   PubMed Web of Science ®Google Scholar
• Grotewold L, Ruther U. Bmp, Fgf and Wnt signalling in programmed cell death and chondrogenesis during vertebrate limb development: the role of Dickkopf-1. Int J Dev Biol 2002;46:943-7
   PubMedGoogle Scholar
• Li J, Sarosi I, Cattley RC, et al. Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia. Bone 2006;39:754-66
   PubMed Web of Science ®Google Scholar
• Qiang YW, Barlogie B, Rudikoff S, Shaughnessy JD Jr. Dkk1-induced inhibition of Wnt signaling in osteoblast differentiation is the underlying mechanism of bone loss in multiple myeloma. Bone 2008;42:669-80
   PubMed Web of Science ®Google Scholar
• Tian E, Zhan F, Walker R, et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003;349:2483-94
   PubMed Web of Science ®Google Scholar
• Kaiser M, Mieth M, Liebisch P, et al. Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma. Eur J Hematol 2008;80:490-4
   PubMed Web of Science ®Google Scholar
• Politou MC, Heath DJ, Rahemtulla A, et al. Serum concentrations of Dickkopf-1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation. Int J Cancer 2006;119:1728-31
   PubMed Web of Science ®Google Scholar
• Haaber J, Abildgaard N, Knudsen LM, et al. Myeloma cell expression of 10 candidate genes for osteolytic bone disease. Only overexpression of DKK1 correlates with clinical bone involvement at diagnosis. Br J Haematol 2008;140:25-35
   PubMed Web of Science ®Google Scholar
• Yaccoby S, Ling W, Zhan F, et al. Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood 2007;109:2106-11
   PubMed Web of Science ®Google Scholar
• Terpos E, Heath DJ, Rahemtulla A, et al. Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-κB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma. Br J Haematol 2006;135:688-92
   PubMed Web of Science ®Google Scholar
• Terpos E, Kastritis E, Roussou M, et al. The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis. Leukemia 2008;22:2247-56
   PubMed Web of Science ®Google Scholar
• Robbiani DF, Chesi M, Bergsagel PL. Bone lesions in molecular subtypes of multiple myeloma. N Engl J Med 2004;351:197-8
   PubMed Web of Science ®Google Scholar
• Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids: potential mechanisms of their deleterious effects on bone. J Clin Invest 1998;102:274-82
   PubMed Web of Science ®Google Scholar
• Ohnaka K, Taniguchi H, Kawate H, et al. Glucocorticoid enhances the expression of dickkopf-1 in human osteoblasts: novel mechanism of glucocorticoid-induced osteoporosis. Biochem Biophys Res Commun 2004;318:259-64
   PubMed Web of Science ®Google Scholar
• Terpos E, Sezer O, Croucher P, Dimopoulos MA. Myeloma bone disease and proteasome inhibition therapies. Blood 2007;110:1098-104
   PubMed Web of Science ®Google Scholar
• San Miguel JF, Sclag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008;359:906-17
   PubMed Web of Science ®Google Scholar
• Oyajobi BO, Garrett IR, Gupta A, et al. Stimulation of new bone formation by the proteasome inhibitor, bortezomib: implications for myeloma bone disease. Br J Haematol 2007;139:434-8
   PubMed Web of Science ®Google Scholar
• Zangari M, Esseltine D, Lee CK, et al. Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma. Br J Haematol 2005;131:71-3
   PubMed Web of Science ®Google Scholar
• Qiang YW, Hu B, Chen Y, et al. Bortezomib induces osteoblast differentiation via Wnt-independent activation of β-catenin/TCF signaling. Blood 2009;113:4319-30
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Kastritis E, Christoulas D, et al. Treatment of patients with relapsed/refractory multiple myeloma (MM) with lenalidomide and dexamethasone with or withour bortezomib depending on prior neurotoxicity: prospective evaluation of the impact of cytogenetic abnormalities and assessment of bone metabolism [abstract 1726]. Blood 2008;112(11):608
   Google Scholar
• Colla S, Zhan F, Xiong W, et al. The oxidative stress response regulates DKK1 expression through the JNK signaling cascade in multiple myeloma plasma cells. Blood 2007;109:4470-7
   PubMedGoogle Scholar
• Terpos E, Politou M, Szydlo R, et al. Autologous stem cell transplantation normalizes abnormal bone remodeling and sRANKL/osteoprotegerin ratio in patients with multiple myeloma. Leukemia 2004;18:1420-6
   PubMed Web of Science ®Google Scholar
• Qiang YW, Shaughnessy JD Jr, Yaccoby S. Wnt3a signaling within bone inhibits multiple myeloma bone disease and tumor growth. Blood 2008;112:374-82
   PubMed Web of Science ®Google Scholar
• Gunn WG, Conley A, Deininger L, et al. A crosstalk between myeloma cells and marrow stromal cells stimulates production of DKK1 and interleukin-6: a potential role in the development of lytic bone disease and tumor progression in multiple myeloma. Stem Cells 2006;24:986-91
   PubMed Web of Science ®Google Scholar
• Fulciniti M, Tassone P, Hideshima T, et al. Anti-DKK1 mAb (BHQ880) as a potential therapeutic for multiple myeloma [abstract 551]. Blood 2007;110:169A
   Google Scholar
• Heath DJ, Chantry AD, Buckle CH, et al. Inhibiting dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma. J Bone Miner Res 2009;24(3):425-36
   PubMed Web of Science ®Google Scholar
• Fulcitini M, Tassone P, Hideshima T, et al. Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood 2009 In press, published online 5 May 2009; doi 10.1182/blood-2008-11-191577
   Google Scholar
• Pozzi S, Yan H, Vallet S, et al. A new anti-Dkk-1 antibody targeting myeloma bone disease [abstract 203]. Clin Lymphoma Myeloma 2009;9(Suppl):104
   Google Scholar
• Derksen PW, Tjin E, Meijer HP, et al. Illegitimate WNT signaling promotes proliferation of multiple myeloma cells. Proc Natl Acad Sci USA 2004;101:6122-7
   PubMed Web of Science ®Google Scholar
• Qiang YW, Endo Y, Rubin JS, Rudikoff S. Wnt signaling in B-cell neoplasia. Oncogene 2003;22:1536-45
   PubMed Web of Science ®Google Scholar
• Edwards CM, Edwards JR, Lwin ST, et al. Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo. Blood 2008;111:2833-42
   PubMed Web of Science ®Google Scholar
• Kansara M, Tsang M, Kodjabachian L, et al. Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice. J Clin Invest 2009;119:837-51
   PubMed Web of Science ®Google Scholar